About Impax Laboratories (NASDAQ:IPXL)

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Receive IPXL News and Ratings via Email

Sign-up to receive the latest news and ratings for IPXL and its competitors with MarketBeat's FREE daily newsletter.

Profitability

Miscellaneous

Impax Laboratories (NASDAQ:IPXL) Frequently Asked Questions

What is Impax Laboratories' stock symbol?

Impax Laboratories trades on the NASDAQ under the ticker symbol "IPXL."

How were Impax Laboratories' earnings last quarter?

Impax Laboratories Inc (NASDAQ:IPXL) released its quarterly earnings data on Thursday, March, 1st. The specialty pharmaceutical company reported $0.11 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.12 by $0.01. The specialty pharmaceutical company earned $182.90 million during the quarter, compared to analyst estimates of $199.13 million. Impax Laboratories had a positive return on equity of 10.42% and a negative net margin of 60.49%. The firm's revenue was down 7.8% on a year-over-year basis. During the same period last year, the business earned $0.16 EPS. View Impax Laboratories' Earnings History.

When will Impax Laboratories make its next earnings announcement?

Where is Impax Laboratories' stock going? Where will Impax Laboratories' stock price be in 2018?

14 brokerages have issued twelve-month price objectives for Impax Laboratories' shares. Their forecasts range from $16.00 to $35.00. On average, they expect Impax Laboratories' stock price to reach $21.86 in the next twelve months. View Analyst Ratings for Impax Laboratories.

What are Wall Street analysts saying about Impax Laboratories stock?

Here are some recent quotes from research analysts about Impax Laboratories stock:

1. According to Zacks Investment Research, "Impax missed estimates for both the counts in the fourth quarter of 2017. However, the company’s epinephrine auto-injector sales have picked up. Meanwhile, Impax is taking steps to reduce costs and improve efficiencies, which may save an estimated $130 million by the end of 2019. The merger with Amneal Pharma is a positive for Impax as it will have a diverse pipeline with more than 300 products under review or late stage development. Shares of the company outperformed the industry in a year’s time. However, Impax faces competition in the brand product market from Parkinson’s disease and CNS disorder focused large pharmaceutical companies. Impax’s Generics segment underperformed in 2017, due to significant pricing erosion complemented by erosion in volume." (3/16/2018)

2. Cantor Fitzgerald analysts commented, "IPXL announced this morning that Robert Stewart will be joining the company as CEO, effective January 25, 2018." (12/15/2017)

Are investors shorting Impax Laboratories?

Impax Laboratories saw a decline in short interest during the month of February. As of February 15th, there was short interest totalling 10,953,468 shares, a decline of 12.0% from the January 31st total of 12,440,931 shares. Based on an average daily trading volume, of 937,420 shares, the short-interest ratio is currently 11.7 days. Currently, 15.8% of the shares of the stock are short sold.

Has Impax Laboratories been receiving favorable news coverage?

News coverage about IPXL stock has been trending positive on Monday, according to Accern. The research firm scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Impax Laboratories earned a daily sentiment score of 0.25 on Accern's scale. They also assigned press coverage about the specialty pharmaceutical company an impact score of 44.40 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Impax Laboratories?

Shares of IPXL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Impax Laboratories' stock price today?

One share of IPXL stock can currently be purchased for approximately $20.85.

How big of a company is Impax Laboratories?

Impax Laboratories has a market capitalization of $1.56 billion and generates $775.79 million in revenue each year. The specialty pharmaceutical company earns $-469,280,000.00 in net income (profit) each year or ($6.52) on an earnings per share basis. Impax Laboratories employs 1,257 workers across the globe.

MarketBeat Community Rating for Impax Laboratories (IPXL)

MarketBeat's community ratings are surveys of what our community members think about Impax Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Impax Laboratories (NASDAQ:IPXL) Analysts' Consensus Rating

MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.

MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.